Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05241574 | Planned Non-operative Management for Rectal Cancer | unknown | Phase 2 | 23 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT01889303 | Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer | unknown | Phase 2 | 100 | Wuhan UniversityOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04177797 | Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT05213637 | Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 430 | Chinese PLA General HospitalOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05225844 | An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | unknown | Phase 2 | 150 | Harbin Medical UniversityOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT04390945 | Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer | unknown | Phase 2 | 62 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 72 | National Taiwan University HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03067493 | RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial(RAMEC) | unknown | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT03939962 | Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05207735 | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.(SCRCA) | unknown | Phase 2 | 73 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 26, 2022 | clinicaltrials |
| NCT04062058 | A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer | unknown | Phase 2 | 82 | Jing Jin, M.D.UNKNOWN | 1 | Jan 24, 2022 | clinicaltrials |
| NCT05204173 | Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis | unknown | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT05200299 | mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer | unknown | Phase 2 | 100 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05168527 | The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03973112 | A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 123 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT04782791 | Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT05183958 | A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer | unknown | Phase 2 | 118 | Zhejiang Cancer HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05184946 | Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma | unknown | Phase 2 | 72 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05185869 | SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer | unknown | Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04981665 | A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05174325 | Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT05171309 | Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | unknown | Phase 2 | 35 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05166772 | Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)in the First-line Treatment of Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 22, 2021 | clinicaltrials |
| NCT05007145 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma(REVO) | unknown | Phase 2 | 92 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02595320 | Capecitabine in Metastatic Breast and GI Cancers(X7-7) | unknown | Phase 2 | 200 | Qamar KhanOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05161143 | Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT04286958 | A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC(ESCC) | unknown | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05130021 | A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer | unknown | Phase 2 | 130 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05138159 | A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05135364 | HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | unknown | Phase 2 | 48 | Yue HanOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05130684 | Neo-NTP-CRT for Locally Advanced ESCC(Neo-NTP-CRT) | unknown | Phase 2 | 43 | National Taiwan University HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05113459 | Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer(RC48-C018) | unknown | Phase 2 | 40 | Guoxin LiOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04764006 | Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study | unknown | Phase 2 | 10 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05103501 | Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy(SINCERE) | unknown | Phase 2 | 54 | Shanghai Chest HospitalOTHER | 0 | Nov 2, 2021 | clinicaltrials |
| NCT05100329 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer | unknown | Phase 2 | 38 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT05095636 | Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 102 | Fudan UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04582981 | Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05077839 | Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC(TOBACO) | unknown | Phase 2 | 184 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04089150 | MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease(MASTERPLAN) | unknown | Phase 2 | 120 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05068206 | A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | unknown | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 20, 2021 | clinicaltrials |
| NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | unknown | Phase 2 | 35 | Shengjing HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT02826837 | LEAC-102 for Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 30 | Taiwan Leader Biotech Corp.INDUSTRY | 0 | Oct 6, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT04006821 | PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma | unknown | Phase 2 | 30 | China Medical University, ChinaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Feb 15, 2022source: clinicaltrials